The Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 2 trial demonstrated a
significant reduction in subsequent coronary revascularization among patients with stable angina and at least 1 coronary
lesion with a fractional flow reserve ≤0.80 who were randomized to percutaneous coronary intervention (PCI) compared
with best medical therapy. The economic and quality-of-life implications of PCI in the setting of an abnormal fractional
flow reserve are unknown.